Prostate cancer (PCa) is the second most common malignant tumor among men worldwide and has an increasing incidence. The main characteristic of PCa is heterogeneity, which includes not only variations of tumor histological characteristics among patients, but also differences in growth, invasion and metastasis speed of tumor cells in the same patient. Recent studies showed that the JARID1D demethylase, which is encoded from the Y chromosome, specifically binds to the promoters of genes related to invasion and metastasis, such as MMP1, MMP2 and MMP3, and demethylate at the promoter through a gene activation marker such as H3K4, so as to inhibit the production of some invasive compounds and reduce the invasive ability of prostate cancer. Meanwhile, knocking down the expression of demethylase JARID1D will improve the metastatic potential of prostate cancer and even promote multiple organ metastasis, including bone metastasis.In this review, we summarize the recent progression on the research on the JARID1D demethylase. We discuss its structure and the enzymatic and regulatory mechanisms, and we review the role of JARID1D in the invasion and metastasis of prostate cancer. We also explore novel intervention targets for PCa therapy.